How to Clear Plaque from Arteries: What Actually Works

Arterial plaque can shrink, but doing so requires aggressive and sustained lowering of LDL cholesterol, typically with prescription medications. The strongest evidence comes from trials using high-intensity statins alone or combined with newer injectable drugs called PCSK9 inhibitors, which have been shown on imaging to measurably reduce plaque volume inside coronary arteries. Lifestyle changes like a Mediterranean diet help slow progression and may offer modest regression, but the “natural artery cleanses” and supplement regimens promoted online have little to no clinical support.

What Plaque Actually Is and Why It Resists Removal

Plaque forms when LDL cholesterol particles slip beneath the inner lining of an artery wall and trigger an immune response. White blood cells arrive, swallow the cholesterol, and become bloated “foam cells.” Over time, these foam cells die and accumulate into a fatty, inflamed core. The artery wall remodels around it, adding fibrous tissue and sometimes calcium. Foam cells arise not just from immune cells but also from smooth muscle cells and even stem cells within the vessel wall, which helps explain why plaque is so difficult to dislodge once established.¹

This complexity matters because “clearing plaque” is not like unclogging a drain. The process involves reversing years of biological remodeling: cholesterol must be pulled back out of foam cells, inflammation must cool down, and the fibrous cap over the plaque must thicken and stabilize. Researchers measure these changes using tiny ultrasound probes threaded directly into coronary arteries, a technique called intravascular ultrasound (IVUS). The metric you will see referenced most often is “percent atheroma volume,” or PAV, which captures how much of the artery wall is occupied by plaque. Even a one-percentage-point drop in PAV is considered clinically meaningful, because it correlates with fewer heart attacks down the line.

Aggressive LDL Lowering With Statins and PCSK9 Inhibitors

The most reliable way to shrink plaque is to drive LDL cholesterol far below conventional targets. High-intensity statin therapy alone has been shown in a meta-analysis to reduce PAV by roughly one percentage point.² That may sound small, but remember that plaque typically grows over a lifetime. Stopping that growth and reversing it, even modestly, shifts the trajectory of cardiovascular risk.

Adding a PCSK9 inhibitor on top of a statin roughly doubles the effect. In the GLAGOV trial, patients already on statins who received the PCSK9 inhibitor evolocumab saw PAV decrease by about 0.95%, while the placebo group’s plaque actually inched upward. Evolocumab also induced plaque regression in a larger share of patients compared to placebo: roughly 64% versus 47%.³ In the PACMAN-AMI trial, which tested the PCSK9 inhibitor alirocumab in heart attack patients already on high-intensity statins, PAV dropped by about 2.1% with the drug versus 0.9% with placebo over a year.⁴

The meta-analysis pooling these and similar trials found that high-intensity statins alone lowered LDL by about 59 mg/dL, while adding a PCSK9 inhibitor brought the total LDL reduction to about 98 mg/dL. PAV shrank nearly twice as much with the combination, dropping around 1.9 percentage points versus about 1.0 with statin monotherapy.² The pattern is consistent: the lower you push LDL, the more plaque regresses. Beyond just shrinking volume, imaging studies suggest these therapies also stabilize plaques by thickening the fibrous cap that prevents rupture, which is the event that actually triggers a heart attack.⁵

One nuance worth knowing: a short-term subgroup analysis from the FITTER trial found that evolocumab did not significantly reduce plaque volume over its study period compared to placebo at the individual-lesion level, though overall plaque volume still dropped in both groups. The researchers noted that the short follow-up may explain the lack of a between-group difference.⁶ The takeaway is that plaque regression requires sustained treatment. You do not see dramatic changes in weeks; the signal becomes clearer over many months to a year or more.

Ezetimibe as an Add-On to Statins

Not everyone can tolerate high-dose statins, and some people’s cholesterol stays stubbornly high even at maximum doses. Ezetimibe, a pill that blocks cholesterol absorption in the gut, is often added in these cases. A meta-analysis comparing ezetimibe-statin combination therapy to statin monotherapy found that the combination significantly reduced total atheroma volume, though it did not clearly change the lumen (the open channel inside the artery) or the thickness of the fibrous cap.⁷ In other words, ezetimibe helps chip away at plaque volume when added to a statin, but the effect is more modest than what PCSK9 inhibitors deliver. For patients who cannot access or afford PCSK9 inhibitors, though, it remains a useful second-line option.

Diet and Lifestyle Changes

Medication gets the strongest imaging data, but diet and exercise are not just window dressing. The CORDIOPREV trial followed patients with coronary heart disease for seven years and found that those assigned to a Mediterranean diet saw a measurable decrease in carotid artery wall thickness, a marker of atherosclerosis progression. The low-fat diet comparison group did not see the same improvement.⁸ Data from the PREDIMED trial suggests that a Mediterranean diet can reduce the probability of acute cardiovascular events by about a third.⁹

Plant-based diets have also been linked to reduced cardiovascular mortality and, in some cases, to reversal of coronary artery disease.¹⁰ Much of that evidence comes from older studies by Dean Ornish and Caldwell Esselstyn using intensive lifestyle programs that combined strict plant-based eating with exercise, stress management, and social support. It is hard to tease apart how much of the benefit was the diet alone versus the entire lifestyle overhaul. Still, dietary patterns emphasizing vegetables, whole grains, legumes, nuts, and olive oil while minimizing processed food and red meat consistently show up as protective in cardiovascular research.

Exercise helps through multiple pathways: lowering blood pressure, improving cholesterol ratios, reducing inflammation, and improving how the body handles blood sugar. There is no single imaging trial proving that running three times a week will shrink your coronary plaques by a specific amount, but the indirect effects on risk factors are well established. Where lifestyle interventions really shine is in preventing plaque from getting worse and in supporting the effectiveness of medications. A patient who takes a statin but eats fast food daily and never moves will get less benefit than one who pairs medication with a reasonable diet and regular physical activity.

Targeting Inflammation Directly

Atherosclerosis is fundamentally an inflammatory disease, not just a cholesterol-storage problem. This insight led to the landmark CANTOS trial, which tested canakinumab, a drug that blocks a specific inflammatory signal called interleukin-1β. The trial enrolled patients who had already had a heart attack and were on standard therapy including statins. Canakinumab lowered the rate of recurrent heart attacks, strokes, and cardiovascular deaths, and it did so without changing cholesterol levels at all.¹¹

The finding was a proof of concept: quelling arterial inflammation can reduce cardiovascular events even when lipids are already controlled.¹² Canakinumab has not become a routine cardiovascular drug, partly because of cost and partly because it also slightly increased the risk of fatal infections. But the principle it established is shaping how researchers think about future treatments: the ideal therapy would lower both cholesterol and inflammation simultaneously.

What About GLP-1 Drugs Like Semaglutide?

GLP-1 receptor agonists, the class of drugs that includes semaglutide (Ozempic, Wegovy) and liraglutide, have generated enormous excitement for their cardiovascular benefits. Lab studies show they dampen several inflammatory pathways involved in plaque formation, and animal research suggests anti-atherosclerotic effects that go beyond their impact on blood sugar or body weight.¹³

However, when researchers tested semaglutide directly to see if it reduces plaque inflammation in people with type 2 diabetes and existing cardiovascular disease, the results were disappointing. A randomized trial using PET-MRI to measure arterial inflammation found no significant difference between semaglutide and placebo after 26 weeks of treatment.¹⁴ GLP-1 drugs clearly reduce cardiovascular events in large outcome trials, but the mechanism may not be a direct attack on plaque inflammation. It may work through weight loss, improved metabolic health, or other indirect routes. For now, do not count on these drugs as a plaque-regression therapy specifically, even though they are valuable cardiovascular medicines for other reasons.

Stents and Surgery for Stable Disease

If medication can shrink plaque, you might wonder whether mechanically reopening a clogged artery is better. For people having an active heart attack, stenting or bypass surgery is lifesaving. But for stable coronary artery disease, where the patient has plaque buildup but is not in an acute crisis, the picture is different. A meta-analysis of randomized trials found that placing a stent in patients with stable disease showed no clear benefit over medical therapy alone for preventing death, heart attacks, unplanned repeat procedures, or angina.¹⁵

This does not mean stents are useless. They remain critical in acute situations and for patients whose symptoms are not adequately controlled by medications. But for the person whose doctor found some plaque on a scan and who feels fine, jumping to an invasive procedure is rarely better than optimizing medications and lifestyle. The evidence consistently supports a “medication first” approach for stable patients.

Supplements and Alternative Therapies That Fall Short

Search for “clear arteries naturally” and you will find no shortage of claims about vitamin K2, chelation therapy, and various supplements. The evidence for most of these is either absent or actively discouraging.

Vitamin K2 has attracted interest because lab studies show it can inhibit calcification in smooth muscle cells in a dish.¹⁶ That sounds promising until you see the human trial data. A randomized, double-blind trial in elderly men with significant aortic valve calcification found that two years of vitamin K2 plus vitamin D supplementation did not slow calcification progression compared to placebo.¹⁷ What works in a petri dish often fails to translate to living people, and vitamin K2 for arterial calcification appears to be one of those cases.

Chelation therapy, which involves intravenous infusions of EDTA to bind metals in the bloodstream, has a longer and more complicated history. A Cochrane review found no evidence that chelation reduced deaths, heart attacks, or angina compared to placebo in patients with coronary artery disease.¹⁸ One large trial (TACT) did find a modest overall reduction in cardiovascular events, with a more pronounced benefit in patients with diabetes.¹⁹ A systematic review similarly noted that the strongest signals for chelation benefit appeared in people with diabetes and severe peripheral artery disease.²⁰ Replication trials are ongoing, but the current evidence is not strong enough to recommend chelation for the general population with heart disease. It remains firmly in the “needs more research” category, and no major cardiology guidelines endorse it as standard therapy.

HDL Mimetics and the “Good Cholesterol” Problem

For years, researchers hoped that boosting HDL cholesterol, the so-called good cholesterol, might pull plaque out of artery walls. This led to the development of HDL mimetics, synthetic particles designed to mimic the cholesterol-removal function of HDL. One such agent, CER-001, showed plaque regression in patients with more extensive disease at baseline but not in those with less plaque, and only at a specific dose.²¹ Another mimetic based on apolipoprotein A-I Milano, tested in the MILANO-PILOT trial, did not produce additional plaque regression beyond what patients were already getting from statins.²²

A review of the field concluded that HDL mimetics have largely failed to prove a clinical benefit to date.²³ One agent, CSL-112, was still in late-stage clinical trials at the time of that review and may yet show results. But the broader lesson is that simply raising HDL or mimicking it does not reliably shrink plaque. The relationship between HDL and heart disease turned out to be more complicated than the early “good cholesterol” framing suggested.

The Gut Microbiome Angle

One of the more surprising research threads in atherosclerosis involves bacteria in your gut. When gut microbes digest certain nutrients found in red meat, eggs, and full-fat dairy, they produce a compound called trimethylamine, which the liver converts into trimethylamine N-oxide (TMAO). Higher TMAO levels have been linked to greater plaque formation, more inflammation in artery walls, and a higher risk of cardiovascular events.²⁴ TMAO appears to promote endothelial dysfunction and platelet activation, both of which make plaques more dangerous.²⁵

Researchers are investigating drugs that block the microbial enzymes responsible for producing TMAO, and early results in animal models are encouraging. No TMAO-lowering drug is approved for human use yet, but the concept is interesting because it suggests a whole new angle on plaque prevention that sits outside the traditional lipid-lowering approach. In the meantime, the most practical implication is dietary: reducing intake of foods high in choline, carnitine, and lecithin (concentrated in red meat and organ meats) may help keep TMAO levels lower, which aligns with the same dietary patterns already recommended for heart health.

Sleep Apnea and Plaque You Did Not Know About

Most discussions of arterial plaque focus on cholesterol and diet, but sleep quality matters more than most people realize. A study using coronary CT angiography found that patients with severe obstructive sleep apnea had roughly three times the prevalence of unstable (non-calcified or mixed) plaques compared to patients without sleep apnea. The overall plaque burden also increased with sleep apnea severity, and the severity of apnea was an independent predictor of these dangerous plaque types after accounting for age and other risk factors.²⁶

The mechanism likely involves repeated drops in blood oxygen during sleep, which trigger surges of stress hormones and inflammation throughout the cardiovascular system. This makes treating sleep apnea with CPAP or other therapies a potentially important and often overlooked component of a plaque-reduction strategy. If you snore heavily, wake up tired, or have been told you stop breathing during sleep, getting screened is worth the effort for reasons that go well beyond feeling less groggy in the morning.

Nanotechnology and Future Approaches

Looking further ahead, researchers are exploring the use of nanoparticles to deliver drugs directly to atherosclerotic plaques. The appeal is obvious: a targeted delivery system could concentrate anti-inflammatory or lipid-lowering agents exactly where they are needed, reducing side effects and potentially improving efficacy.²⁷ Some nanoparticle systems are also being developed for diagnostic purposes, designed to light up inflamed plaques on imaging scans so doctors can identify which patients are at highest risk of a rupture event.

None of these technologies are available clinically yet, and the jump from proof-of-concept studies to routine patient care is notoriously long in cardiovascular medicine. But they represent a genuinely different approach from anything currently available. Rather than flooding the whole body with a drug and hoping enough reaches the artery wall, nanomedicine aims to put the therapy exactly where the plaque is. Combined with better imaging to track plaque changes over time, this could eventually allow physicians to treat arterial disease with a precision that today’s tools cannot match.